Abstract
Background: Brain metastases develop in approximately 10-25% of patients with metastatic breast cancer (MBC) and are associated with a very poor prognosis. Case Report: We report the case of a 40-year-old woman with MBC and associated lung, bone, liver, and brain metastases, who experienced a time to progression of several months with eribulin after whole-brain radiotherapy (WBRT), 2 lines of chemotherapy, and 1 line of hormonal therapy, maintaining a good toxicity profile. Discussion: Eribulin, in association with local treatment such as WBRT, can be well tolerated and effective in achieving a long progression-free survival and a good control of brain metastases in patients with MBC who have received multiple lines of treatment. The vascular remodeling properties of eribulin, combined with brain radiotherapy, might facilitate the passage of eribulin across the blood brain barrier, improving brain response. Conclusion: Our anecdotal experience suggests that eribulin may have a potentially beneficial effect on brain metastases while maintaining a good systemic control of the disease in patients with MBC.
| Original language | English |
|---|---|
| Pages (from-to) | 29-33 |
| Number of pages | 5 |
| Journal | Oncology (Switzerland) |
| Volume | 94 |
| DOIs | |
| Publication status | Published - Jul 1 2018 |
Fingerprint
Keywords
- Brain metastasis
- Breast cancer
- Eribulin
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer : A Stone in a Pond? / Catania, Giovanna; Malaguti, Paola; Gasparro, Simona; Cognetti, Francesco; Vidiri, Antonello; Fabi, Alessandra.
In: Oncology (Switzerland), Vol. 94, 01.07.2018, p. 29-33.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer
T2 - A Stone in a Pond?
AU - Catania, Giovanna
AU - Malaguti, Paola
AU - Gasparro, Simona
AU - Cognetti, Francesco
AU - Vidiri, Antonello
AU - Fabi, Alessandra
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Background: Brain metastases develop in approximately 10-25% of patients with metastatic breast cancer (MBC) and are associated with a very poor prognosis. Case Report: We report the case of a 40-year-old woman with MBC and associated lung, bone, liver, and brain metastases, who experienced a time to progression of several months with eribulin after whole-brain radiotherapy (WBRT), 2 lines of chemotherapy, and 1 line of hormonal therapy, maintaining a good toxicity profile. Discussion: Eribulin, in association with local treatment such as WBRT, can be well tolerated and effective in achieving a long progression-free survival and a good control of brain metastases in patients with MBC who have received multiple lines of treatment. The vascular remodeling properties of eribulin, combined with brain radiotherapy, might facilitate the passage of eribulin across the blood brain barrier, improving brain response. Conclusion: Our anecdotal experience suggests that eribulin may have a potentially beneficial effect on brain metastases while maintaining a good systemic control of the disease in patients with MBC.
AB - Background: Brain metastases develop in approximately 10-25% of patients with metastatic breast cancer (MBC) and are associated with a very poor prognosis. Case Report: We report the case of a 40-year-old woman with MBC and associated lung, bone, liver, and brain metastases, who experienced a time to progression of several months with eribulin after whole-brain radiotherapy (WBRT), 2 lines of chemotherapy, and 1 line of hormonal therapy, maintaining a good toxicity profile. Discussion: Eribulin, in association with local treatment such as WBRT, can be well tolerated and effective in achieving a long progression-free survival and a good control of brain metastases in patients with MBC who have received multiple lines of treatment. The vascular remodeling properties of eribulin, combined with brain radiotherapy, might facilitate the passage of eribulin across the blood brain barrier, improving brain response. Conclusion: Our anecdotal experience suggests that eribulin may have a potentially beneficial effect on brain metastases while maintaining a good systemic control of the disease in patients with MBC.
KW - Brain metastasis
KW - Breast cancer
KW - Eribulin
UR - http://www.scopus.com/inward/record.url?scp=85050766790&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050766790&partnerID=8YFLogxK
U2 - 10.1159/000489066
DO - 10.1159/000489066
M3 - Article
VL - 94
SP - 29
EP - 33
JO - Oncology
JF - Oncology
SN - 0030-2414
ER -